

ACL estimates the burden hours for this collection of information as follows:

|                                       | Number of respondents | Number of responses per respondent | Average burden hours per response | Total burden hours |
|---------------------------------------|-----------------------|------------------------------------|-----------------------------------|--------------------|
| New Grantees .....                    | 75                    | 1                                  | 52                                | 3,900              |
| Continuations and Final Reports ..... | 200                   | 1                                  | 22                                | 4,400              |
| Total .....                           |                       |                                    |                                   | 8,300              |

Dated: May 18, 2017.

**Daniel P. Berger,**

*Acting Administrator and Assistant Secretary for Aging.*

[FR Doc. 2017-10634 Filed 5-23-17; 8:45 am]

**BILLING CODE 4154-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Mentored Career Development (K) and Conference (R13) Award Application Review 2017-10.

*Date:* June 19, 2017.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Two Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual Meeting).

*Contact Person:* John P Holden, Ph.D., Scientific Review Officer, National Institute of Health, National Institute of Biomedical Imaging and Bioengineering, Bethesda, MD 20892, (301) 496-8947, [john.holden@nih.gov](mailto:john.holden@nih.gov).

*Name of Committee:* National Institute of Biomedical Imaging and Bioengineering Special Emphasis Panel; Quantum Review Meeting (2017/01).

*Date:* June 28, 2017.

*Time:* 09:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Crystal Gateway Marriott, 1700 Jefferson Davis Highway, Arlington, VA 22202.

*Contact Person:* Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451-4794, [dennis.hlasta@nih.gov](mailto:dennis.hlasta@nih.gov).

Dated: May 18, 2017.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-10550 Filed 5-23-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App. 2), notice is hereby given of the joint meeting of the National Cancer Advisory Board (NCAB) and NCI Board of Scientific Advisors (BSA).

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting and Podcasting Web site (<http://videocast.nih.gov>).

A portion of the National Cancer Advisory Board meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning

individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Advisory Board *Ad Hoc* Subcommittee on Cancer Centers.

*Open:* June 19, 2017, 5:30 p.m. to 7:00 p.m.

*Agenda:* Discussion on Cancer Centers.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland 20814.

*Contact Person:* Dr. Henry P. Ciolino, Executive Secretary, NCAB *Ad Hoc* Subcommittee on Cancer Centers, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 2W102, Bethesda, MD 20892, (240) 276-5624, [henry.ciolino@nih.gov](mailto:henry.ciolino@nih.gov).

*Name of Committee:* National Cancer Advisory Board *Ad Hoc* Subcommittee on Population Science, Epidemiology and Disparities.

*Open:* June 19, 2017, 7:30 p.m. to 9:00 p.m.

*Agenda:* Discussion on Population Science, Epidemiology and Disparities.

*Place:* Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, Maryland 20814.

*Contact Person:* Dr. Deborah Winn, Executive Secretary, NCAB *Ad Hoc* Subcommittee on Population Science, Epidemiology and Disparities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 4E344, Bethesda, MD 20892, (240) 276-6755, [winnde@mail.nih.gov](mailto:winnde@mail.nih.gov).

*Name of Committee:* National Cancer Advisory Board and NCI Board of Scientific Advisors.

*Open:* June 20, 2017, 8:00 a.m. to 4:30 p.m.

*Agenda:* Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors; NCI Board of Scientific Advisors Concepts Review, NCI Acting Director's report.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 7W444, Bethesda, MD 20892, 240-276-6340, [grayp@mail.nih.gov](mailto:grayp@mail.nih.gov).

*Name of Committee:* National Cancer Advisory Board.

*Closed:* June 20, 2017, 4:45 p.m. to 5:30 p.m.

*Agenda:* Review of NCAB grant applications.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 7W444, Bethesda, MD 20892, 240-276-6340, [grayp@mail.nih.gov](mailto:grayp@mail.nih.gov).

*Name of Committee:* National Cancer Advisory Board and NCI Board of Scientific Advisors.

Open: June 21, 2017, 8:00 a.m. to 12:00 p.m.

*Agenda:* Joint meeting of the National Cancer Advisory Board and NCI Board of Scientific Advisors; NCI Board of Scientific Advisors Concepts Review.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Paulette S. Gray, Ph.D., Director, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, Room 7W444, Bethesda, MD 20892, 240-276-6340, [grayp@mail.nih.gov](mailto:grayp@mail.nih.gov).

*Name of Committee:* NCI Board of Scientific Advisors *Ad Hoc* Subcommittee on HIV and AIDS Malignancy.

Open: June 21, 2016, 1:00 p.m. to 5:00 p.m.

*Agenda:* Discussion on HIV and AIDS Malignancy.

*Place:* National Institutes of Health, Building 31, C-Wing, 6th Floor, Room 10, 9000 Rockville Pike, Bethesda, MD 20892.

*Contact Person:* Dr. Robert Yarchoan, Executive Secretary, NCI Board of Scientific Advisors *Ad Hoc* Subcommittee on HIV and AIDS Malignancy, National Cancer Institute, National Institutes of Health, 10 Center Drive, Building 10, Room 6N106, Bethesda, MD 20892, (301) 496-0328, [robert.yarchoan@nih.gov](mailto:robert.yarchoan@nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: NCAB: <http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm>, BSA: <http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 18, 2017.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2017-10549 Filed 5-23-17; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Call for Nominations for the Non-Federal Members of the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC)

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Secretary of Health and Human Services, in accordance with the 21st Century Cures Act, is seeking nominations for the non-federal members of the ISMICC.

**FOR FURTHER INFORMATION CONTACT:** Pamela Foote, Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, 14E53C, Rockville, MD 20857; telephone: 240-276-1279; email: [pamela.foote@samhsa.hhs.gov](mailto:pamela.foote@samhsa.hhs.gov).

#### SUPPLEMENTARY INFORMATION:

##### I. Background and Authority

The ISMICC is established in accordance with section 6031 of the 21st Century Cures Act, and the Federal Advisory Committee Act, 5 U.S.C. App., as amended, to report to the Secretary, Congress, and any other relevant federal department or agency on advances in serious mental illness (SMI) and serious emotional disturbance (SED), research related to the prevention of, diagnosis of, intervention in, and treatment and recovery of SMI, SED, and advances in access to services and support for adults with SMI or children with SED. In addition, the ISMICC will evaluate the effect that federal programs related to serious mental illness have on public health, including public health outcomes such as (A) rates of suicide, suicide attempts, incidence and prevalence of SMIs, SEDs, and substance use disorders, overdose, overdose deaths, emergency hospitalizations, emergency room boarding, preventable emergency room visits, interaction with the criminal justice system, homelessness, and unemployment; (B) increased rates of

employment and enrollment in educational and vocational programs; (C) quality of mental and substance use disorders treatment services; or (D) any other criteria as may be determined by the Secretary. Finally, the ISMICC will make specific recommendations for actions that agencies can take to better coordinate the administration of mental health services for adults with SMI or children with SED. Not later than 1 (one) year after the date of enactment of the 21st Century Cures Act, and 5 (five) years after such date of enactment, the ISMICC shall submit a report to Congress and any other relevant federal department or agency.

##### II. Committee Composition

The ISMICC will consist of federal members listed below or their designees and non-federal public members.

*Federal Membership:* The ISMICC will be composed of the following federal members or their designees:

- The Secretary of Health and Human Services;
- The Assistant Secretary for Mental Health and Substance Use;
- The Attorney General;
- The Secretary of the Department of Veterans Affairs;
- The Secretary of the Department of Defense;
- The Secretary of the Department of Housing and Urban Development;
- The Secretary of the Department of Education;
- The Secretary of the Department of Labor;
- The Administrator of the Centers for Medicare and Medicaid Services; and
- The Commissioner of the Social Security Administration.

In accordance with the Committee's authorizing statute, the Committee shall also "include not less than 14 non-Federal public members appointed by the Secretary of Health and Human Services." 21st Century Cures Act, section 6031(e)(2).

All non-Federal public members are appointed as Special Government Employees for their service on the ISMICC, of which:

(A) At least 2 members shall be an individual who has received treatment for a diagnosis of a serious mental illness;

(B) At least 1 member shall be a parent or legal guardian of an adult with a history of a serious mental illness or a child with a history of a serious emotional disturbance;

(C) At least 1 member shall be a representative of a leading research, advocacy, or service organization for adults with a serious mental illness;